ORMP - Oramed Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

Oramed Pharmaceuticals's activity chart (see below) currently has 22 price targets and 34 ratings on display.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 65.33% of the time, taking 776 days on average.

Most recent stock forecast was given by from HC WAINWRIGHT on 09-Sep-2024. First documented stock forecast 03-Dec-2013.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 20-May-2024

2 years 2 months 12 days ago
(09-Sep-2024)

2/5 (40%)

$19.21 (150.20%)

1449

Hold Since 12-Jan-2023

$2

3 years 6 months 4 days ago
(17-May-2023)

2/4 (50%)

$-1.38 (-40.83%)

175

Buy Since 11-Mar-2020

$35

4 years 6 months 5 days ago
(16-May-2022)

1/2 (50%)

$11.62 (49.70%)

320

Buy Since 18-Feb-2022

$20

4 years 9 months 3 days ago
(18-Feb-2022)

0/1 (0%)

$10.16 (103.25%)

Buy Since 03-Dec-2020

$40

5 years 12 days ago
(09-Nov-2021)

1/2 (50%)

$12.76 (46.84%)

181

Show more analysts

Please expand the browser size to see the chart

What is ORMP (Oramed Pharmaceuticals) average time for price targets to be met?

On average it took 776 days for the stock forecasts to be reached, with an average price target met ratio of 65.33%.

Which analyst most recently updated their price target on ORMP (Oramed Pharmaceuticals)?

Which analyst has the most public recommendations on ORMP (Oramed Pharmaceuticals)?

has 0 price targets and 0 ratings on ORMP

Which analyst is the currently most bullish on ORMP (Oramed Pharmaceuticals)?

James Molloy with the highest potential upside of $36.43

Which analyst is the currently most reserved on ORMP (Oramed Pharmaceuticals)?

Edward Nash with the lowest potential downside of -$2.67
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?